Saturday 17 October 2026
Export AAPG’s income statement to Excel — free account
Ascentage Pharma Group International - Unsponsored ADR
AAPG Healthcare Biotechnology
Ascentage Pharma Group International - Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $82.1 million, down 38.9% from fiscal 2024.
15.37
0.68
+4.63%
Follow AAPG
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | 16.50 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | 48.45 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 600 | 567 | 767 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.05 | 0.24 | 0.11 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 31 | 31 | 134 | 82 | ||||
| Gross margin, % | — | — | — | — | — | — | 100.00 | 86.24 | 97.03 | 91.48 | |||||
| EBT | — | — | — | — | — | — | 31 | (128) | (54) | (177) | |||||
| EBT margin, % | — | — | — | — | — | — | 100.00 | (420.24) | (40.31) | (215.30) | |||||
| Net income | — | — | — | — | — | — | 0 | (128) | (54) | (177) | |||||
| Depreciation | — | — | — | — | — | — | — | 11 | 11 | 11 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.47 | 0.43 | 1.78 | 0.92 | ||||
| Earnings | — | — | — | — | — | — | (1.99) | (1.86) | (0.72) | (2.00) | |||||
| Cash flow | — | — | — | — | — | — | 0.00 | (1.42) | (0.20) | (1.89) | |||||
| Capex | — | — | — | — | — | — | 0.00 | (0.11) | (0.04) | (0.04) | |||||
| Free cash flow | — | — | — | — | — | — | 0.00 | (1.53) | (0.25) | (1.93) | |||||
| Book value | — | — | — | — | — | — | 0.00 | 0.14 | 0.50 | 2.14 | |||||
| Shares, m | — | — | — | — | — | — | 66 | 71 | 76 | 89 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.20 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (100) | (15) | (168) | ||||
| Capex | — | — | — | — | — | — | — | (8) | (3) | (4) | |||||
| Free cash flow | — | — | — | — | — | — | — | (108) | (19) | (172) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 56 | 42 | 186 | ||||
| Total debt | — | — | — | — | — | — | — | 247 | 229 | 283 | |||||
| Net debt | — | — | — | — | — | — | — | 97 | 56 | (70) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | 10 | 38 | 191 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (74.04) | (15.81) | (38.41) | ||||
| ROIC | — | — | — | — | — | — | 0.00 | (67.80) | (30.31) | (87.57) | |||||
| ROE | — | — | — | — | — | — | 0.00 | 0.00 | (234.96) | (155.65) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025
Charts ten years each
Ascentage Pharma Group International - Unsponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ANAB AnaptysBio, Inc. | $1.5B | — (loss-making) | 220× | −7.98% (below 0%: shrinking) | n/m | −141.60% (below 0%: shrinking) | 100.00% | (135.53%) | Compare |
| RAPP Rapport Therapeutics, Inc. | $1.4B | — (loss-making) | — | — | n/m | −64.75% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| AAPG Ascentage Pharma Group International - Unsponsored ADR | $1.4B | — | — | — | — | +17.74% (above 0%: growing) | — | — | |
| OMER Omeros Corporation | $1.4B | 9.5× | 2.1× | +35.46% (above 0%: growing) | n/m | +118.70% (above 0%: growing) | 97.20% | 0.26% | Compare |
| INBX Inhibrx Biosciences, Inc. | $1.3B | — (loss-making) | — (loss-making) | +992.44% (above 0%: growing) | n/m | +0.12% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ORIC Oric Pharmaceuticals, Inc. | $1.3B | — (loss-making) | — | — | n/m | −3.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| TYRA Tyra Biosciences, Inc. | $1.3B | — (loss-making) | — | — | n/m | −31.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GHRS GH Research PLC | $1.3B | — (loss-making) | — | — | n/m | −66.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NKTR Nektar Therapeutics | $1.3B | — (loss-making) | — (loss-making) | −9.34% (below 0%: shrinking) | n/m | −65.73% (below 0%: shrinking) | 100.00% | (417.94%) | Compare |
| Median of peers | $1.3B | — | — | +13.74% | — | −48.04% | 98.60% | 0.00% |
Ascentage Pharma Group International - Unsponsored ADR (AAPG) key facts
- Concern: Ascentage Pharma Group International - Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $82.1 million, down 38.9% from fiscal 2024.
- Concern: Ascentage Pharma Group International - Unsponsored ADR reported a net loss of $176.8 million, or a loss of $2.00 per share, for fiscal 2025.
- Ascentage Pharma Group International - Unsponsored ADR (AAPG) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
- As of October 16, 2026, AAPG traded at $15.37, a market capitalization of $1.4 billion.
- Return on equity was −155.7% and debt-to-equity 3.70.
- Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 0.81 (distress zone) for fiscal 2025.